Beijing Biostar Pharmaceuticals Co., Ltd.

R&D

R&D Pipeline

Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.

Assets

Indication

Combo

Development area

Pre-clinical

IND

Phase I

Phase II

Phase III

NDA

Commercial Rights

Utidelone Injection

Advanced breast cancer

Xeloda

Global

Xeloda

Global

Advanced non-small cell lung cancer

Monotherapy

Global

Monotherapy

Global

Breast cancer neoadjuvant

Global

Solid tumors

Monotherapy／PD-1

Global

Breast cancer brain metastasis

Xeloda

Global

Lung cancer brain metastasis

VEGF mAb

Global

Glioblastoma

VEGF mAb

CN & US

Global

Utidelone Capsule

Solid tumors

Monotherapy

Global

Monotherapy

Global

Advanced breast cancer

Xeloda

Global

Advanced ovarian cancer

Monotherapy

CN & US

Global

Advanced liver cancer

Monotherapy

Global

Advanced gastric and esophageal cancers

PD-1

CN & US

Global

Utidelone nano-injection

Solid tumors

TBD

Global

Utidelone antibody-drug conjugate

Solid tumors

TBD

Global

BG22

Solid tumors

TBD

Global

BG18

Solid tumors

TBD

Global

BG44

Solid tumors

TBD

Global

Note:

Abbreviations: Xeloda: capecitabine; AC: anthracycline and cyclophosphamide; VEGF mAb: vascular endothelial growth factor monoclonal Antibody; TBD: to be determined.